{
  "ticker": "DHR",
  "cik": "0000313616",
  "company_name": "DANAHER CORP /DE/",
  "filing_date": "2025-02-20",
  "item1_summary": " In order to compete effectively, we must retain longstanding relationships with major customers and continue to grow our business . Cost containment efforts by governments and the private sector, particularly in the healthcare industry, are also resulting in increased emphasis on products that reduce costs and improve efficiency and effectiveness . In addition, significant shifts in industry market share have occurred and may in the future occur in connection with product problems .\n The company's growth depends in part on the timely development and commercialization of new and enhanced products and services based on technological innovation . New, disruptive technologies may also emerge and displace existing technologies resulting in an adverse effect on the Company’s business and financial statements . Our success depends on several factors, including our ability to identify customer needs and preferences and predict future needs .\n If we fail to accurately predict future customer needs or fail to produce viable technologies, we may invest heavily in R&D of products and services that do not lead to significant revenue . The healthcare industry and related industries that we serve have undergone, and are in the process of undergoing, significant changes in an effort to reduce (and increase the predictability of) costs .\n The PPACA, healthcare austerity measures in other countries and other potential healthcare reform changes and government austerity measures have reduced and may further reduce the amount of government funding or reimbursement available to customers or end-users . Other countries, as well as some private payors, also control the price of healthcare products, directly or indirectly, through reimbursement, payment, pricing or coverage limitations .\n Government and private healthcare providers and payors around the world are increasingly utilizing managed care for the delivery of healthcare services . Payors are also seeking to improve price predictability in an effort to mitigate exposure to future price increases . Global economic uncertainty or deterioration can also adversely impact government funding and reimbursement . These changes are changing the way healthcare is delivered, reimbursed and funded .\n In 2024 approximately 58% of our sales from continuing operations were derived from customers outside the U.S. In addition, many of our manufacturing operations, suppliers and employees are located outside the United States . All of the factors described above can adversely affect our business and financial statements . We plan to continue to increase our sales and presence outside the US., particularly in the high-growth markets .\n In 2024 we generated approximately 12% of our sales from continuing operations from China . Political, economic, legal, compliance, social and business conditions in China generally can adversely influence our business and financial statements . China’s government continues to play a significant role in regulating industry development by imposing sector-specific policies .\n Our growth depends in part on the growth of the markets which we serve, and visibility into our markets can be limited . Our quarterly sales and profits depend substantially on the volume and timing of orders received during the quarter, which are difficult to forecast . Our growth can suffer if the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality .\n ds on customers’ capital spending budgets, government funding policies and interest rates, and matters of public policy and government budget, fiscal and monetary dynamics as well as product and economic cycles can affect the spending decisions of these entities . Demand for our products and services is also sensitive to changes in customer order patterns, which may be affected by announced price changes, marketing or promotional programs .\n Global operations expose us to risks associated with public health crises, including epidemics and pandemics such as COVID-19 . Compliance with new or changing laws, regulations or industry standards relating to AI may impose significant costs and may limit our ability to develop, deploy or use AI technologies . Failure to respond to this evolving landscape may result in legal liability, regulatory action, or brand and reputational harm .\n Certain of our businesses rely on relationships with business partners and other third-parties for development, supply and/or marketing of certain products, potential products and technologies . As such epidemics/pandemics evolve we may experience volatility and declines in demand that are unanticipated in timing or magnitude, which could adversely affect our business and financial statements .\n Our ability to grow revenues, earnings and cash flow at or above our historic rates depends in part upon our ability to identify and successfully acquire and integrate businesses at appropriate prices and realize anticipated synergies . We may not be able to consummate acquisitions at rates similar to the past, which could adversely impact our business . Competition for acquisitions and investments has resulted and may result in higher purchase prices .\n Acquisitions, investments, joint ventures and strategic relationships involve a number of risks and challenges, including but not limited to the following, any of which can adversely affect our business and financial statements . Businesses, technologies, services and products that we acquire or invest in sometimes under-perform relative to our expectations and the price that we paid .\n We are not always able to achieve cost savings or other synergies anticipated in connection with acquisitions, investments, joint ventures or strategic relationships . We often enter into post-closing financial arrangements such as purchase price adjustments, earn-out obligations and indemnification obligations, which can have unpredictable financial results and/or lead to disputes and litigation . We may have interests that diverge from those of our joint venture partners .\n Investing in or making loans to early-stage companies often entails a high degree of risk . The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us . We may not always achieve the strategic, technological, financial, financial or commercial benefits we anticipate; we may lose our investment or fail to recoup our loan; or our investment may be illiquid for a greater-than-expected period of time .\n We continually assess the strategic fit of our existing businesses and may divest, spin-off, split-off or otherwise dispose of businesses for strategic, financial or other reasons . The Dispositions and any future, similar transactions pose risks and challenges that could negatively impact our business and financial statements . The resolution of these contingencies has not had a material effect on our business or financial statements but there can be no assurance that this favorable pattern will continue .\n We could incur significant liability if our dispositions of any of Fortive Corporation, Envista Holdings Corporation or Veralto Corporation is determined to be a taxable transaction . A court could disregard the allocation of assets and liabilities agreed to between Danaher and such other parties . Each of these risks could negatively affect our business and financial statements .\n Risks include breaches in, or breaches in security of, our information technology systems or violation of data privacy laws . Errors, defects, security issues or other vulnerabilities in third-party technology could result in errors that could harm our business . These systems, products and services (including those we acquire through business acquisitions) are susceptible to being damaged, or shut down due to attacks by computer hackers, computer viruses, human error or malfeasance .\n Like most multinational corporations, our information technology systems and data have been subject to computer viruses, malicious codes, unauthorized access and other cyber-attacks . Unauthorized tampering, adulteration or interference with our products may also adversely affect product functionality and result in loss of data, risk to patient safety and product recalls .\n Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches . Any businesses that we acquire may further expose us to the risks set forth above . Information technology systems require an ongoing commitment of significant resources to maintain and enhance existing systems and develop new systems .\n Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to €20 million or up to 4% of total worldwide annual turnover for the preceding financial year, whichever is higher, and other administrative penalties . Compliance with the varying data privacy regulations across the U.S. and around the world has required significant expenditures and may require additional expenditures .\n Manufacturing or design defects or “bugs” in, safety or quality issues (or the perception of such issues) with respect to, “off label” use of, or inadequate disclosure of risks relating to the use of products and services that we make or sell (including items that we source from third-parties) can lead to personal injury, death, property damage and/or regulatory violations .\n If any of these facilities, supply chains or systems were to experience a catastrophic loss, it could disrupt operations, delay production and shipments, result in defective products or services, diminish demand, damage customer relationships and our reputation . Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere presents risks to our operations .\n Any such new or additional requirements relating to climate change or other sustainability topics may increase the costs associated with, or disrupt, sourcing, manufacturing and distribution of our products . Failure to adequately address regulatory requirements may result in penalties, loss of business, adverse reputational impacts, diluted market valuations and challenges in attracting and retaining customers and employees .\n The manufacture of many of our products is a highly exacting and complex process . Problems can arise during manufacturing for a variety of reasons, including equipment malfunction, contamination, failure to follow specific protocols and procedures . Any of these manufacturing problems could result in adverse impacts to our business and financial statements . Our financial results are subject to fluctuations in the cost and availability of the supplies that we use in, and the labor we need for, our operations .\n Sustained interruptions in the supply of, or increase in the cost of, key components, raw materials, other commodities and labor can result in production interruptions, delays, extended lead times and inefficiencies . Some of our businesses purchase certain requirements from sole or limited source suppliers for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design .\n Certain of our businesses sell a significant amount of their products to or through key distributors and other channel partners that have valuable relationships with customers and end-users . Adverse developments in the financial condition, performance or purchasing patterns of these distributors and partners can adversely affect our business and financial statements . The levels of inventory maintained by these parties, and changes in those levels, also impacts our results of operations .\n In recent years we faced, and may continue to face, labor availability constraints and labor cost inflation in certain areas of our business . If we are less successful in our recruiting efforts, if we cannot retain and motivate highly skilled workers, or if we experience labor disputes or unionization, our business and financial statements may be adversely affected .\n We own numerous patents, trademarks, copyrights, trade secrets and other intellectual property and licenses to intellectual property owned by others . The intellectual property rights that we obtain are not always sufficiently broad and do not always provide us a significant competitive advantage . We also rely on nondisclosure and noncompetition agreements with employees, consultants and other parties to protect trade secrets .\n The risks are particularly pronounced in countries in which we do business that do not have levels of protection of corporate proprietary information, intellectual property, technology and other assets comparable to the United States . The risks we encounter in such countries include but are not limited to the following: Joint ventures that we participate in can include restrictions that could compromise our control over the joint venture .\n Third-parties from time to time claim that we are infringing or misappropriating their intellectual property rights . Disputes or litigations regarding intellectual property can be costly and time-consuming to defend due to the complexity of many of our technologies . We could lose our rights to critical technology, be unable to license critical technology or sell critical products and services .\n The U.S. government has certain rights with respect to incremental production capacity attributable to, and/or the intellectual property we have developed, using government financing . In times of national emergency the government could control our allocation of manufacturing capacity . We may incur significant costs and diversion of management attention and resources, which could adversely affect our business and financial statements .\n Our outstanding debt has increased significantly as a result of acquisitions, and we may incur additional debt in the future . The levels of demand for our products can exceed our capacity to meet such demand on a timely basis or at all . Failure to comply with the covenants that apply to our indebtedness could adversely affect our business and financial statements .\n Our debt level and related debt service obligations can have negative consequences, including requiring us to dedicate significant cash flow from operations to the payment of principal and interest on our debt . If our credit ratings are downgraded or put on watch for a potential downgrade, we may not be able to sell additional debt securities or borrow money in the amounts .\n As of December 31, 2024, the net carrying value of our goodwill and other intangible assets totaled approximately $59.1 billion . Significant negative industry or economic trends, disruptions to our business, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of our assets, changes in the structure of our business .\n Changes in our tax rates or exposure to additional income tax liabilities or assessments can affect our profitability . The Company also faces exchange rate risk from its investments in subsidiaries owned and operated in foreign countries . The amount of income taxes we pay is subject to ongoing audits by U.S. federal, state and local tax authorities, such as the audits described in MD&A and the Company’s Consolidated Financial Statements .\n Any further changes to the tax system in the United States or in other countries could also adversely affect our financial statements . Military conflicts (such as the conflicts between Russia and Ukraine and in the Middle East) can adversely affect the financial situation . The OECD has released several components of its comprehensive plan (e.g. the Pillar Two 15% global minimum tax framework) that have been adopted and expanded by many taxing authorities .\n In 2024, Russia, Ukraine and Israel sales combined accounted for less than 1% of the Company’s sales . Military conflicts also heighten other risks disclosed in this Annual Report, any of which can adversely affect our business and financial statements . Legal, Regulatory, Compliance and Reputational Risks include legal, regulatory and compliance risks .\n Trade tensions between China and other countries (including the U.S.) have escalated, with countries imposing significant additional tariffs on a wide range of imported goods . The full impact of these tariffs on the Company and our business partners remains uncertain . There can be no assurance that our internal controls and compliance systems, including our Code of Conduct, protect us from acts committed by employees, agents or business partners of ours .\n Our businesses are subject to extensive regulation . Failure to comply with those regulations could adversely affect our business and financial statements . We operate in many parts of the world that have experienced governmental corruption to some degree . We also rely on our suppliers to adhere to our Supplier Code of Conduct, and violations of such code of conduct could affect business .\n Certain of our subsidiaries have limited business dealings in countries subject to sanctions . Less than 5% of our 2024 sales were made to the U.S. federal government . Government contracts that have been awarded to us following a bid process can become the subject of a bid protest by a losing bidder, which could result in loss of the contract . The laws governing government contracts differ from the laws governing private contracts .\n Failure to comply (or any alleged or perceived failure to comply) with the regulations referenced above or any other regulations can result in fines, fines, damages, civil and administrative penalties, injunctions, consent decrees, suspensions or losses of regulatory approvals, recall or seizure of products, operating restrictions, disbarment from selling to certain governmental agencies . Compliance with regulations can also affect our returns on investment, require us to incur significant expenses .\n We are subject to or otherwise responsible for a variety of litigation and other legal and regulatory proceedings in the course of our business . Failure to comply with these rules can result in withdrawal of certifications needed to sell our products and services . The types of claims made in lawsuits include claims for compensatory damages, punitive and consequential damages .\n The defense of these lawsuits can divert our management’s attention, we from time to time incur significant expenses in defending these lawsuits, and we can be required to pay damage awards or settlements . Any insurance or indemnification rights that we have may be insufficient or unavailable to protect us against such losses . There can be no assurance that our liabilities in connection with current and future litigation will not exceed our estimates .\n Certain of our products are subject to regulation by the FDA, by other federal and state governmental agencies, by comparable agencies of other countries and by certain accrediting bodies . Failure to comply with those regulations could adversely affect our business and financial statements . The global healthcare regulatory environment has become increasingly stringent and unpredictable . For example, expanded FDA regulation of laboratory-developed tests may delay and add to the cost of commercialization .\n We cannot guarantee that we will be able to obtain regulatory clearance (such as 510(k) clearance) for our new products or modifications to (or additional indications or uses of) existing products . Failure to meet these requirements can adversely impact our business and financial statements in the applicable geographies . Even after initial regulatory clearance or approval, we are subject to periodic inspection by these regulatory authorities, and when safety issues arise we can be required to amend conditions for use of a product .\n Failure to obtain required regulatory clearances or approvals before marketing our products can lead to FDA Form 483 Inspectional Observations, warning letters, notices to customers, declining sales, loss of customers, market share, remediation and increased compliance costs . Failure to comply with those regulations could adversely affect our business and financial statements .\n Our products can be subject to human clinical trials, the results of which may be unexpected, or perceived as unfavorable by the market . Unexpected or inconsistent clinical data from existing or future clinical trials can adversely impact our ability to obtain product approvals, our position in, and our markets in which we participate . Off-label marketing of our products could result in substantial penalties .\n Certain modifications to our products may require new 510(k) clearances or other marketing authorizations . FDA may deny those requests outright, require additional performance or clinical data to support any additional indications or impose limitations on the intended use of any cleared products as a condition of clearance . If the FDA or any other regulator determines that we have marketed our products for off-label use, we can be subject to exclusion from participation in government healthcare programs .\n Our operations, products and services are subject to numerous U.S. environmental, health and safety laws and regulations . Failure to comply with any of these laws can result in civil and criminal, monetary and non-monetary penalties and damage to our reputation . There can be no assurance that our compliance program (or the compliance programs of businesses we acquire) will be effective .\n There can be no assurance that our liabilities arising from past or future releases of, or exposures to, hazardous substances will not exceed our estimates or adversely affect our reputation and financial statements . We compete in markets in which we and our customers must comply with supranational, federal, state, local and other jurisdictional regulations, such as regulations governing health and safety, the environment, food and drugs and privacy .\n Our By-laws provide that the sole and exclusive forum for any dispute with us is the Court of Chancery of the State of Delaware . These provisions are not a waiver of, and do not relieve anyone of duties to comply with, federal securities laws including those specifying the exclusive jurisdiction of federal courts under the Securities Act of .\n A court might determine that these provisions of the By-laws are inapplicable or unenforceable in any particular action, in which case we may incur additional litigation-related expenses in such action . The action may result in outcomes unfavorable to us, which could have an adverse impact on our business and financial statements .\n We strive to implement and maintain layered controls designed to prevent and, where necessary, detect and respond to cybersecurity threats . Every year, associates in applicable job categories are required to take information security and protection training as part of the Danaher Annual Training Program . We also conduct regular education and training for our associates through cyber-event simulations .\n Information technology/cybersecurity is one of five topical areas required to be addressed as part of the annual ERM program . IT and cybersecurity risks are scored using the same methodology applied to all other risk categories . Danaher policy requires the reporting of certain cybersecurity incident data to Danaher’s Risk Committee .\n Danaher's cybersecurity program is led by the Company’s Chief Information Security Officer (“CISO”), who reports to the Chief Information Officer . The CISO is supported by the Information Risk Steering Committee . The IRSC supports the CISO and CIO in overseeing and managing information security risks .\n Based on the information we have as of the date of this Annual Report, we do not believe any risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect Danaher's business strategy, results of operations or financial condition, including our business strategy ."
}